Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175301 · ClinicalTrials.gov registry record · Phase 2
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
A Phase 2 study of Malignant Glioma, sponsored by Stony Brook University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04175301: Active Phase 2 study of Malignant Glioma, sponsored by Stony Brook University.
NCT04175301 is a Phase 2 study of Malignant Glioma that is active but no longer recruiting, run by Stony Brook University. The registered enrollment target is 15 participants, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04175301, a Phase 2 study of Malignant Glioma, is active but no longer recruiting, sponsored by Stony Brook University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Hydrogen
Study Locations (1)
New York
- Stony Brook University Medical Center - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175301
The ClinicalTrials.gov registry entry for NCT04175301 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04175301 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04175301 about?
NCT04175301 is a clinical study titled "Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.". This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.
What is the current status of trial NCT04175301?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-10-31. Estimated completion is 2027-09-30.
What conditions does trial NCT04175301 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT04175301?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydrogen (DRUG).
Who is sponsoring clinical trial NCT04175301?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175301 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 2
-
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.